In yesterday’s Wall Street session, Lucira Health Inc. (NASDAQ:LHDX) shares traded at $0.12, down -4.00% from the previous session.
As we calculate the median target price by taking the range between a high of $0.75 and a low of $0.75, we find $0.75. Given the previous closing price of $0.12, this indicates a potential upside of 525.0 percent. LHDX stock price is now -78.32% away from the 50-day moving average and -93.75% away from the 200-day moving average. The market capitalization of the company currently stands at $4.89M.
Brokers who have rated the stock have averaged $0.75 as their price target over the next twelve months.
On April 13, 2021, BofA Securities Downgraded its previous ‘Neutral’ rating to ‘Underperform’ on the stock keeping its target price maintained at $9, while ‘William Blair’ rates the stock as ‘Outperform’.
In other news, Allen Anthony Joseph, Chief Operations Officer sold 4,263 shares of the company’s stock on Dec 20. The stock was sold for $682 at an average price of $0.16. Upon completion of the transaction, the Chief Operations Officer now directly owns 144,925 shares in the company, valued at $17391.0. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 01, Interim CFO Narido Richard Clavano sold 1,583 shares of the business’s stock. A total of $570 was realized by selling the stock at an average price of $0.36. This leaves the insider owning 107,293 shares of the company worth $12875.16. Insiders disposed of 104,079 shares of company stock worth roughly $12489.48 over the past 1 year. A total of 3.40% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in LHDX stock. A new stake in Lucira Health Inc. shares was purchased by CITIGROUP INC during the first quarter worth $74,000. ALPHACENTRIC ADVISORS LLC invested $38,000 in shares of LHDX during the first quarter. In total, there are 46 active investors with 57.10% ownership of the company’s stock.
Thursday morning saw Lucira Health Inc. (NASDAQ: LHDX) opened at $0.1643. During the past 12 months, Lucira Health Inc. has had a low of $0.12 and a high of $9.30. As of last week, the company has a debt-to-equity ratio of 0.48, a current ratio of 1.50, and a quick ratio of 0.80. The fifty day moving average price for LHDX is $0.5535 and a two-hundred day moving average price translates $1.9211 for the stock.
The latest earnings results from Lucira Health Inc. (NASDAQ: LHDX) was released for Jun, 2022. According to the Medical Devices Company, earnings per share came in at -$0.54, missing analysts’ expectations of -$0.34 by -0.2. This compares to -$0.71 EPS in the same period last year. The net profit margin was -67.50% and return on equity was -89.60% for LHDX. The company reported revenue of $34.39 million for the quarter, compared to $14.98 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 129.63 percent. For the current quarter, analysts expect LHDX to generate $32.79M in revenue.
Lucira Health Inc.(LHDX) Company Profile
Lucira Health, Inc., a medical technology company, focuses on the development and commercialization of infectious disease test kits. It develops a testing platform that produces molecular testing services. The company offers LUCIRA COVID-19 All-In-One Test Kit, a COVID-19 test kit; and develops influenza A and B viruses test kits. It has a patent license agreement with Eiken Chemical Co., Ltd.; technical services agreement with Jabil, Inc.; and manufacturing services agreement with Jabil MSA. The company was formerly known as DiAssess Inc. and changed its name to Lucira Health, Inc. in January 2020. Lucira Health, Inc. was incorporated in 2013 and is headquartered in Emeryville, California.